CSIMarket Company Name, Ticker, Customers, else..
 
Ikena Oncology Inc   (NASDAQ: IKNA)
Other Ticker:  
 
 
Price: $1.4600 $0.01 0.690%
Day's High: $1.47 Week Perf: 0.69 %
Day's Low: $ 1.43 30 Day Perf: -5.19 %
Volume (M): 28 52 Wk High: $ 1.94
Volume (M$): $ 41 52 Wk Avg: $1.58
Open: $1.43 52 Wk Low: $1.22



 Market Capitalization (Millions $) 70
 Shares Outstanding (Millions) 48
 Employees 62
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -60
 Cash Flow (TTM) (Millions $) -76
 Capital Exp. (TTM) (Millions $) 0

Ikena Oncology Inc
Ikena Oncology Inc is a biopharmaceutical company that specializes in developing targeted cancer therapies. The company focuses on identifying and developing small molecule drugs that inhibit specific cancer signaling pathways to disrupt tumor growth and progression. They aim to provide innovative solutions for patients with unmet medical needs in various types of cancer. Ikena Oncology Inc was founded in 2016 and is based in Massachusetts, United States.


   Company Address: 645 Summer Street Boston 2210 MA
   Company Phone Number: 273-8343   Stock Exchange / Ticker: NASDAQ IKNA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADAP   -4.68%    
AMGN        0.84% 
BIIB   -3.69%    
CCCC   -7.82%    
CRIS   -4.95%    
RLAY   -16.63%    
• View Complete Report
   



Product Service News

Ikena Oncology's Promising Path to Progress: Optimized Formulation and Robust Revenue Growth

Published Thu, Jan 18 2024 9:06 PM UTC

In a significant development, Ikena Oncology Inc., a renowned biotechnology company focused on developing innovative cancer therapies, has shared key updates and outlined their priorities for the future. Highlighting their progress with the optimized formulation of their leading drug candidate IK-930 and their remarkable revenue growth, Ikena Oncology is poised to make signi...
Ikena Oncology Inc

Ikena Oncology Inc's Catastrophic Blow in Latest Fiscal Period Sends Shockwaves Through Biotech Industry



The stock market is a constantly evolving machine, influenced by various factors that affect the performance of individual companies. One such company, Ikena Oncology Inc, recently released its third-quarter 2023 earnings report. Let's analyze the highlights and delve into some interesting facts surrounding the market's response to this news.
Financial Performance:
During the third quarter of 2023, Ikena Oncology Inc witnessed a notable improvement in its loss per share. The loss decreased from $0.48 per share in the previous year to $0.40 per share, indicating a positive trend. Additionally, the company observed an improvement in earnings per share, which rose from $0.44 to $1.19 per share when compared to the previous reporting period.
Ikena Oncology Inc

Ikena Oncology Inc reports a surprising deficit of $-0.44 per Share for the second quarter of 2023 earnings season, raising concerns for the future

Ikena Oncology Inc (IKNA) has proven to be a standout performer in the Biotechnology & Pharmaceuticals sectors with its strong revenue growth of 424.607% year on year. Despite experiencing a net deficit of $-17.115 million in the second quarter of 2023, the company's top-line improvement is noteworthy compared to the revenue decline observed among most of its industry peers.
In the financial second quarter of 2023, Ikena Oncology Inc generated an impressive $2.00 million in revenue, indicating a surge from the previous reporting period where revenue tumbled by -62.281% to $5.31 million. This substantial increase in revenue demonstrates the company's ability to resist the negative market trend within the Biotechnology & Pharmaceuticals sectors.
Ikena Oncology Inc

Ikena Oncology Inc Shows Promising Progress with Improved Financial Performance in Q1 2023

Ikena Oncology Inc, a company operating in the Healthcare sector, has recorded a cumulative net loss of $-66 million in 12 months ending in the first quarter of 2023. This has resulted in a negative return on assets (ROA) of -36.43%. This indicates that the company's assets are not generating sufficient revenue or profit, leading to a negative return on investment.
In comparison, within the Healthcare sector, there are 480 other companies that have a higher return on assets, highlighting that Ikena Oncology Inc is not performing as well as its competitors.
However, the company has seen an improvement in its overall ranking for return on assets. The total ROA ranking has advanced to 3434 in the first quarter of 2023 from 4351 in the fourth quarter of 2022. This could indicate that the company is taking steps towards improving its financial performance.
For the financial first quarter of 2023, Ikena Oncology Inc has reported a loss of $-0.39 per share, which is an improvement compared to the loss of $-0.47 per share a year before. However, this is an increase in loss compared to the prior financial reporting period, where the company reported a loss of $-0.38 per share.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com